-- 据周五在香港交易所发布的公告显示，丽珠医药集团（上海证券交易所代码：000513，香港证券交易所代码：1513）已获得中国国家药品监督管理局批准，开展JP-1366片剂的临床试验。 该批准的适应症为JP-1366片剂与合适的抗生素联合使用，用于根除幽门螺杆菌。
Related Articles
Asia
Joyvio Food's Loss Narrows 96% in Q1
Joyvio Food's (SHE:300268) attributable loss narrowed 96% to 7.84 million yuan in the first quarter from 180.9 million yuan in the year-ago period, according to a Monday filing by parent company Legend Holdings (HKG:3396) with the Hong Kong bourse.Loss per share at the Chinese agricultural products company came in at 0.0450 yuan compared with 1.0385 yuan in the prior-year period.Revenue declined 71% to 194.3 million yuan from 677.5 million yuan in the year-ago period.
$HKG:3396$SHE:300268
Asia
Shengyi Technology's 2025 Profit Surges 92%, Revenue Up 39%
Shengyi Technology (SHA:600183) posted full-year attributable net profit of 3.33 billion yuan in 2025, up 92% from 1.74 billion yuan in 2024.Earnings per share rose to 1.38 yuan from 0.73 yuan, according to a filing with the Shanghai bourse over the weekend.The electronic components manufacturer's revenue climbed 39% year over year to 28.4 billion yuan from 20.4 billion yuan.
$SHA:600183
Asia
East Money Information's Q1 Profit Up 38%, Revenue Rises 44%
East Money Information (SHE:300059) posted first-quarter attributable net profit of 3.74 billion yuan, up 38% from 2.72 billion yuan the previous year.Earnings per share rose to 0.2364 yuan from 0.1719 yuan, according to a filing with the Shenzhen bourse over the weekend.The financial services provider's operating revenue climbed 44% year over year to 5.03 billion yuan from 3.49 billion yuan.
$SHE:300059